Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Dezaguanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.41 |
| ▸ | BCL2 known ✓ | P10415 | 1/20 | 0.33 |
| ▸ | MCL1 known ✓ | Q07820 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 4/20 | 0.79 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | C1S | P09871 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dezaguanine SCHEMBL19439015 | 1.00 | PNP (0.79) | PNPABL1RIN1QTRT1PARP1 | |
| Dezaguanine SCHEMBL10911163 | 0.91 | PNP (0.74) | PNPABL1RIN1QTRT1PARP1 | |
| Dezaguanine SCHEMBL4184 | 0.89 | PNP (1.00) | PNPABL1RIN1QTRT1PARP1 | |
| Diaziquone SCHEMBL17891330 | 0.77 | PNP (0.46) | PNPMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL13663973 | 0.72 | PNP (0.62) | PNPPARP1BCL2MCL1MEN1 | |
| SCHEMBL16303465 | 0.70 | PNP (0.51) | PNPPARP1BCL2MCL1MEN1 | |
| Guanine SCHEMBL4830552 | 0.69 | KDM4E (0.53) | PNPKDM4EALDH1A1MAPT | |
| SCHEMBL13664043 | 0.67 | PNP (0.48) | PNPPARP1KDM4EALDH1A1 | |
| Adenine SCHEMBL5663794 | 0.66 | CYP1A2 (0.43) | PNPBLMTDP1 | |
| Guanine SCHEMBL27542045 | 0.65 | HSD17B10 (0.56) | PNPKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9118 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20250320177-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORP (US) | 2025-10-16 | — | — | US | claimed |
| EP-4543960-A1 | COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | Hongene Biotech Corporation (US) | 2025-04-30 | — | — | EP | claimed |
| EP-4524131-A1 | SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | AlonBio Ltd. (IL) | 2025-03-19 | — | — | EP | claimed |
| US-20250034192-A1 | COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORP (US) | 2025-01-30 | — | — | US | claimed |
| US-12202803-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | ALONBIO LTD. (IL) | 2025-01-21 | — | — | US | claimed |
| US-12180140-B2 | Compounds and methods for liquid phase oligonucleotide synthesis | HONGENE BIOTECH CORPORATION (US) | 2024-12-31 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| US-12110546-B2 | Tertiary amine substituted coumarin compounds and uses as fluorescent labels | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-10-08 | — | — | US | claimed |
| WO-2008062466-A2 | CINNAMIC ACID, VANILLIC ACID AND BENZOFURAN DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION AND CANCER | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2008-05-29 | — | — | WO | claimed |
| WO-2008039254-A2 | RNA NANOPARTICLES AND NANOTUBES | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-04-03 | — | — | WO | claimed |
| WO-2007059116-A2 | GELDANAMYCIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ABRAXIS BIOSCIENCE, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| US-20060079472-A1 | Methods for treating angiogenesis | ANGIOSYN, INC. | 2006-04-13 | — | — | US | claimed |
| US-20040092583-A1 | Treatment for inhibiting neoplastic lesions | SHANAHAN-PRENDERGAST ELIZABETH (IE) | 2004-05-13 | — | — | US | claimed |
| EP-1351678-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | Shanahan-Prendergast, Elizabeth (IE) | 2003-10-15 | — | — | EP | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| US-4761478-A | BACTERICIDES, VIRICIDES | WARNER-LAMBERT COMPANY (US) | 1988-08-02 | — | — | US | claimed |
| EP-0103417-B1 | 3-DEAZAGUANINE SULPHONIC ACID SALTS | WARNER-LAMBERT COMPANY (US) | 1986-10-29 | — | — | EP | claimed |
| EP-0103417-A1 | 3-Deazaguanine sulphonic acid salts | WARNER-LAMBERT COMPANY (US) | 1984-03-21 | — | — | EP | claimed |